XTX Topco’s Lantern Pharma LTRN Stock Holding History

XTX Topco’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,624	Closed	-$39.9K	–	2959
2025 Q2	$39.9K	Buy	+12,624	New	+$42.6K	﹤0.01%	2063

Other funds holding LTRN

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

XTX Topco's LTRN Position: Q3 2025 in Review

XTX Topco sold out of Lantern Pharma (LTRN) in Q3 2025, closing a stake of 12,624 shares — an estimated $39.9K sold.

XTX Topco first reported a position in LTRN in Q2 2025 and held it in 1 quarter. The position peaked at $39.9K in Q2 2025. 30 funds tracked by Wall St. Rank hold LTRN as of Q3 2025.

XTX Topco reported no remaining Lantern Pharma position as of Q3 2025 after selling out during the quarter.
XTX Topco sold 12,624 Lantern Pharma shares in Q3 2025, an estimated $39.9K.
XTX Topco first reported a position in Lantern Pharma in Q2 2025 and held it in 1 quarter.
XTX Topco's Lantern Pharma position peaked at $39.9K in Q2 2025.
30 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2025.

Based on XTX Topco's 13F filing for Q3 2025, filed 14 Nov 2025.